Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)
Latest Information Update: 22 May 2024
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLASSIC-MS
- Sponsors EMD Serono Research & Development Institute
Most Recent Events
- 22 May 2024 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 28 Jun 2022 Primary results presented at the 8th Congress of the European Academy of Neurology
- 26 Feb 2022 Primary Results for CLASSIC-MS assessing terms of long-term mobility and disability beyond the treatment courses patients received in the ORACLE MS trial,presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022